Cell-permeable succinate prodrugs rescue mitochondrial respiration in cellular models of acute acetaminophen overdose

PLoS One. 2020 Apr 6;15(4):e0231173. doi: 10.1371/journal.pone.0231173. eCollection 2020.

Abstract

Acetaminophen is one of the most common over-the-counter pain medications used worldwide and is considered safe at therapeutic dose. However, intentional and unintentional overdose accounts for up to 70% of acute liver failure cases in the western world. Extensive research has demonstrated that the induction of oxidative stress and mitochondrial dysfunction are central to the development of acetaminophen-induced liver injury. Despite the insight gained on the mechanism of acetaminophen toxicity, there still is only one clinically approved pharmacological treatment option, N-acetylcysteine. N-acetylcysteine increases the cell's antioxidant defense and protects liver cells from further acetaminophen-induced oxidative damage. Because it primarily protects healthy liver cells rather than rescuing the already injured cells alternative treatment strategies that target the latter cell population are warranted. In this study, we investigated mitochondria as therapeutic target for the development of novel treatment strategies for acetaminophen-induced liver injury. Characterization of the mitochondrial toxicity due to acute acetaminophen overdose in vitro in human cells using detailed respirometric analysis revealed that complex I-linked (NADH-dependent) but not complex II-linked (succinate-dependent) mitochondrial respiration is inhibited by acetaminophen. Treatment with a novel cell-permeable succinate prodrug rescues acetaminophen-induced impaired mitochondrial respiration. This suggests cell-permeable succinate prodrugs as a potential alternative treatment strategy to counteract acetaminophen-induced liver injury.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetaminophen / administration & dosage
  • Acetaminophen / adverse effects*
  • Acetaminophen / pharmacology
  • Aged
  • Analgesics, Non-Narcotic / administration & dosage
  • Analgesics, Non-Narcotic / adverse effects*
  • Analgesics, Non-Narcotic / pharmacology
  • Blood Platelets / metabolism
  • Cell Membrane Permeability / drug effects*
  • Cell Respiration / drug effects*
  • Chemical and Drug Induced Liver Injury / drug therapy
  • Chemical and Drug Induced Liver Injury / metabolism
  • Drug Overdose / drug therapy*
  • Drug Overdose / metabolism
  • Electron Transport Complex I / antagonists & inhibitors
  • Hep G2 Cells
  • Hepatocytes / metabolism
  • Humans
  • Male
  • Mitochondria / drug effects
  • Mitochondria / metabolism*
  • Prodrugs / pharmacokinetics*
  • Succinic Acid / pharmacokinetics*

Substances

  • Analgesics, Non-Narcotic
  • Prodrugs
  • Acetaminophen
  • Succinic Acid
  • Electron Transport Complex I

Grants and funding

This work was funded by Swedish government project and salary funding for clinically oriented medical research ALF-grant F 2014/354 to E.E., Regional research and development grants (Southern healthcare region, Sweden grant 170083 to E.E.;, The Crafoord Foundation grant 2017-0776 to E.E., and The Royal Physiographic Society in Lund grant 20141112 to M.J.H.). Additionally, this study was partially funded by NeuroVive Pharmaceutical AB (Lund, Sweden). NeuroVive Pharmaceutical provided support in the form of salaries for authors [S.P., J.K.E., I.C., E.E., and M.J.H.]. The specific roles of these authors are articulated in the ‘author contributions’ section. The funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.